Table 1. Eligibility criteria for the systematic review of outcomes used in the dementia with Lewy bodies literature.

	Inclusion criteria	Exclusion criteria
Publication year	•    Any
Language	•    No restriction for abstract screening
Types of articles	•    Scientific articles published in peer-reviewed journals with available full texts	•    Popular articles •    Editorials, commentaries etc. •    Study protocols •    Abstracts only •    Conference abstracts •    Trial registries
Study design	•    Comparative clinical trials (regardless of randomization) •    Intervention trials with pre-/post assessments regardless of randomization, case reports	•    Observational studies •    Reviews, meta analysis (for further trials)
Population/ Setting	•    People with dementia with Lewy bodies (DLB) •    18 years and older; all sexes	•    Parkinson’s disease (with and without mild cognitive impairment; PD-MCI) •    Atypical parkinsonism (e.g., PPS, MSA) •    Other dementias (e.g., AD, FTD) •    Mixed study samples (e.g., Involving participants with different dementia subtypes) without separate reporting for Individuals with DLB
Interventions	Any pharmacological, surgical Or non-pharmacological approach for treating motor and non-motor symptoms in Individuals with DLB at any disease stage and in any setting (e.g., outpatients as well as inpatients)
Comparators	Any:       •    None       •    Placebo/Passive control groups/Wait-list       •    Active control groups (comparison of different pharmacological/ surgical/non-pharmacological interventions)
Outcomes	Any:       •    Standardized quantitative assessments, including neurological examinations, assessments and tests, and questionnaires (self-and proxy-rating) across all domains, e.g.;     ○  Disease severity, motor- and non-motor symptoms     ○  Patient-Reported Outcome Measures (PROMs) including quality of life     ○  Biomarkers, imaging outcomes     ○  Changes in housing and care situation (e.g., institution)       •    Carer outcomes included in the patient targeted interventions will be considered (cf. Rigby 2021: https://pubmed.ncbi.nlm.nih.) gov/33554912/)       •    Qualitative approaches to evaluate intervention success across all domains (e.g., outcomes obtained through patient interviews, focus groups)       •    Economic evaluation outcomes (cost analysis, cost-effectiveness analysis, cost-utility analysis, cost-benefit analysis)